Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)-Reference-Cited by-同舟云学术

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)

Published:2013-06 Issue:6 Volume:24 Page:1513-1525
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Vulsteke C.,Lambrechts D.,Dieudonné A.,Hatse S.,Brouwers B.,van Brussel T.,Neven P.,Belmans A.,Schöffski P.,Paridaens R.,Wildiers H.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/6/1513/13788949/mdt008.pdf

Reference63 articles.

1. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients. The FNCLCC PACS 01 Trial;Roché;J Clin Oncol,2006

2. Physical and psychosocial recovery in the year after primary treatment of breast cancer;Ganz;J Clin Oncol,2011

3. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer;Hasset;J Natl Cancer Inst,2006

4. Dose strategies for anticancer drugs: the good, the bad and body-surface area;Felici;Eur J Cancer,2002

5. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy;Rudek;Eur J Cancer,2004

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polymorphism of Transporter Genes Contributes to Variations in Treatment Outcomes and Adverse Events in Platinum Based- Chemotherapy- Treated Oral Cancer Patients;Precision Oncogenomics;2024-04-08

2. Association between genetic variants of membrane transporters and the risk of high-grade hematologic adverse events in a cohort of Mexican children with B-cell acute lymphoblastic leukemia;Frontiers in Oncology;2024-01-10

3. Pharmacogenomics of Cancer Chemotherapy: Transporter Polymorphisms and Drug Response;Interdisciplinary Cancer Research;2024

4. Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy;Translational Oncology;2022-12

5. Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer;Journal of Personalized Medicine;2022-10-04